I am a breastfeeding mother and i want to know if it is safe to use Amjodaronum? Is Amjodaronum safe for nursing mother and child? Does Amjodaronum extracts into breast milk? Does Amjodaronum has any long term or short term side effects on infants? Can Amjodaronum influence milk supply or can Amjodaronum decrease milk supply in lactating mothers?
- DrLact safety Score for Amjodaronum is 5 out of 8 which is considered Unsafe as per our analyses.
- A safety Score of 5 indicates that usage of Amjodaronum may cause serious side effects in breastfed baby.
- Our study of different scientific research indicates that Amjodaronum may cause moderate to high side effects or may affect milk supply in lactating mother.
- Our suggestion is to use safer alternate options rather than using Amjodaronum .
- It is recommended to evaluate the advantage of not breastfeeding while using Amjodaronum Vs not using Amjodaronum And continue breastfeeding.
- While using Amjodaronum Its must to monitor child for possible reactions. It is also important to understand that side effects vary largely based on age of breastfed child and time of medication in addition to dosage.
- Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.
A published case of infant hypothyroidism. Others have reported lab controlled cases with harmless effect in breastfed babies.
Breastmilk and infant serum levels of Amjodaronum and its active metabolite are somewhat unpredictable, but can be high during breastfeeding. The infant receives an estimated dose of Amjodaronum plus desethylAmjodaronum ranging from 3.5 to 45% of the mother's weight-adjusted Amjodaronum dose, with a median dose of about 11%.[1][2][3][4] Infant serum levels of the drug plus metabolite range from 14 to 74% of simultaneous maternal levels, with the higher values reflecting transplacental passage of the drug.[2][3][4] In addition to possible cardiac effects, these compounds contain a large amount of iodine which may be released during metabolism. Thyroid dysfunction was reported in one breastfed infant. Even if the drug were discontinued at birth, the mother would continue to excrete Amjodaronum and its metabolite (and possibly large amounts of iodine) into breastmilk for days to weeks. Some investigators believe that breastfeeding can be undertaken during maternal Amjodaronum use with periodic monitoring of infant cardiac and thyroid function status,[5][6] especially if only a single dose of Amjodaronum is given.[7] Infant serum levels of Amjodaronum and desethylAmjodaronum may be useful for ruling out cardiac effects of the drug. If hypothyroidism develops, therapy should be promptly initiated.
Several infants who breastfed without apparent harm during maternal Amjodaronum therapy have been reported.[2][3][4][10] One mother took Amjodaronum during the last 5 weeks of pregnancy and until one week after delivery. She was also taking metoprolol throughout pregnancy and at the time of delivery. Possible signs of hypothyroidism occurred transiently in her breastfed infant at 9 and 24 days of age. This was possibly caused by Amjodaronum or iodine from Amjodaronum in breastmilk, although residual Amjodaronum from transplacental passage is also a possible contributing factor; no abnormalities in cornea or the lungs were found.[4]
Relevant published information was not found as of the revision date. However, if Amjodaronum causes hypothyroidism in the mother, her milk supply could be diminished.
Disclaimer:
Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. We do not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.